ISIS Stock UPDATES Isis Pharmaceuticals (ISIS) 30.40 08/02/2014

New Post Public Reply Private Reply Replies (0) Message Board

Aug 2, 2014 at 5:04 PM

Isis Pharmaceuticals (ISIS) 30.40 $ISIS

Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy
PR Newswire - Fri Aug 01, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the initiation of a pivotal Phase 3 study evaluating ISIS-SMNRx in infants with spinal muscular atrophy (SMA), the most common genetic cause of infant mortality. Isis plans to dose the first infant in this study within the next few weeks, at which time Isis will earn an $18 million milestone payment from its development partner, Biogen Idec. The Phase 3 study, ENDEAR, is the first of several planned studies in a broad and comprehensive late-stage clinical development program for ISIS-SMNRx. Isis plans to initiate a second pivotal study in children with SMA later this year.

Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call
PR Newswire - Mon Jul 28, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast:

Isis Pharma Initiates Phase II Study on ISIS-APO(a) - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 5:50PM CDT
Isis Pharmaceuticals, Inc. (ISIS) initiated a phase II study on ISIS-APO(a) in patients suffering from high lipoprotein(a) -- Lp(a).

ISIS Pharmaceuticals, Inc. is The Best Stock Today
David Williamson, The Motley Fool - Motley Fool - Sun Jul 20, 4:20PM CDT
The Motley Fool's Better Stock Today tournament has declared a winner! Among the 32 companies pitted against each other our reader's voices your voice were heard loud and clear : Isis Pharmaceuticals is the best stock today. David Williamson,...

Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-APO(a) Rx in Patients with High Lp(a)
PR Newswire - Thu Jul 17, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 2 study evaluating ISIS-APO(a)Rx in patients with high lipoprotein(a), or Lp(a), an independent risk factor for cardiovascular disease. Patients with high levels of Lp(a) have an increased risk of atherosclerosis, coronary heart disease, aortic stenosis, heart attack and stroke. ISIS-APO(a)Rx is designed to reduce Lp(a) by inhibiting the production of apolipoprotein(a). Isis plans to develop ISIS-APO(a)Rx to treat patients with high Lp(a) levels who are at high risk of experiencing life-threatening cardiovascular events.

Isis Pharmaceuticals receives USD1m milestone for advancing ISIS-TTR Rx for treatment of familial amyloid polyneuropathy
M2 - Wed Jul 16, 9:08AM CDT
Novel drug company Isis Pharmaceuticals (NasdaqGS:ISIS) said on Wednesday that it has earned a USD1m milestone payment related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).

Critical Alerts For Cninsure, Freeport-McMoRan, Level 3 Communications, Electronic Arts, and Isis Pharmaceuticals Released By InvestorsObserver
PR Newswire - Wed Jul 16, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CISG, FCX, LVLT, EA, and ISIS.

Isis Pharmaceuticals Earns $1 Million from GSK for Advancing ISIS-TTR Rx
PR Newswire - Wed Jul 16, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).

Biotech Equities Technical Momentum -- Research on Organovo, Prana Biotechnology, Isis Pharma, and Pharmacyclics
PR Newswire - Mon Jul 14, 6:04AM CDT
On Friday, July 11, 2014, the NASDAQ Composite ended at 4,415.49, up 0.44%, the Dow Jones Industrial Average advanced 0.17%, to finish the day at 16,943.81, and the S&P 500 closed at 1,967.57, up 0.15%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 712.90, up 0.14%, with the index also advancing 10.01% in the previous three months. Investor-Edge has initiated coverage on the following equities: Organovo Holdings Inc. (NYSE MKT: ONVO), Prana Biotechnology Ltd (NASDAQ: PRAN), Isis Pharmaceuticals Inc. (NASDAQ: ISIS) and Pharmacyclics Inc. (NASDAQ: PCYC). Free technical research on ONVO, PRAN, ISIS and PCYC can be downloaded upon signing up at:

Is This the Crown Jewel of the ISIS Pipeline?
Brian Wilson, The Motley Fool - Motley Fool - Tue Jul 08, 1:01PM CDT
ISIS Pharmaceuticals is a drug developer that is most famous for its RNA interference (RNAi) technology. Although early clinical progress in RNAi was slow due to crippling toxicity and delivery issues, ISIS Pharma (and its peers) have truly refined...

Watch for Isis Pharmaceuticals to Potentially Rebound After Falling 6.71% Yesterday
Comtex SmarTrend(R) - Mon Jul 07, 6:04PM CDT
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $33.03 to a high of $35.36. Yesterday, the shares fell 6.7%, which took the trading range below the 3-day low of $34.51 on volume of 2.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Isis Pharmaceuticals to Speak at Pharmica Consulting's West Coast SharePoint Conference
PRWeb - Mon Jul 07, 4:31AM CDT
As part of its continued service to the industry, Pharmica will host its 11th SharePoint conference in San Diego, CA on September 30 and October 1, 2014. The two-day conference will highlight real-world case studies and feature interactive discussions that help business users better understand how SharePoint can be leveraged to streamline everyday activities.

19.0% Return Seen to Date on SmarTrend Isis Pharmaceuticals Call (ISIS)
Comtex SmarTrend(R) - Wed Jul 02, 5:09PM CDT
SmarTrend identified an Uptrend for Isis Pharmaceuticals (NASDAQ:ISIS) on May 27th, 2014 at $29.71. In approximately 1 month, Isis Pharmaceuticals has returned 19.00% as of today's recent price of $35.35.

Isis Pharmaceuticals earns USD1m pre-licensing payment for Hepatitis B Virus Programme
M2 - Wed Jul 02, 7:39AM CDT
Novel drugs company Isis Pharmaceuticals (NasdaqGS:ISIS) said on Wednesday that it has earned a USD1m for the advancement of the programme to develop antisense drugs to treat hepatitis B virus (HBV) from GlaxoSmithKline (GSK).

Isis Pharmaceuticals Earns $1 Million From GSK for Advancing Hepatitis B Virus Program
PR Newswire - Wed Jul 02, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million payment from GlaxoSmithKline (GSK) related to the advancement of its program to develop antisense drugs to treat hepatitis B virus (HBV).

Why GW Pharmaceuticals Could be the Next Marijuana Bubble Stock to Pop
George Budwell, The Motley Fool - Motley Fool - Sun Jun 29, 10:30AM CDT
Marijuana stocks have soared this year as more states decriminalize the drug's recreational and medical uses. Even so, most companies developing marijuana-based products are years away from turning a profit, suggesting that a fair amount of this...

Watch for Isis Pharmaceuticals to Potentially Rebound After Falling 2.58% Yesterday
Comtex SmarTrend(R) - Fri Jun 27, 4:24PM CDT
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $34.70 to a high of $35.80. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of $34.80 on volume of 3.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Better Stock Today Challenge: Gilead vs. Isis Pharmaceuticals
David Williamson, The Motley Fool - Motley Fool - Thu Jun 26, 1:45PM CDT
In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other, and you, the reader, will determine the winner. Today it's the Final! Motley Fool health...

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....